



## **Cytokinetics Files Replacement Shelf Registration Statement**

November 10, 2008 10:05 PM EST

SOUTH SAN FRANCISCO, CA, Nov 10, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). The shelf registration statement, if declared effective by the SEC, will allow the Company to raise up to \$100 million through the sale of securities, which may consist of common stock, preferred stock and warrants. Once this shelf registration statement becomes effective, the Company may issue registered securities, from time to time, in one or more separate offerings or other transactions, with the size, price and terms to be determined at the time of issuance. Cytokinetics has no immediate plans to raise funds under this shelf registration statement.

This new shelf registration statement is intended to replace the Company's current shelf registration statement, which was originally filed in June 2005. The June 2005 shelf registration statement permitted the issuance of up to \$100 million of registered securities. Due to sales made previously under the June 2005 shelf registration statement, approximately \$10 million worth of registered securities currently remains available under this shelf registration statement. The June 2005 shelf registration statement will expire upon the earlier of the new shelf registration statement becoming effective or 180 days following December 1, 2008.

Registered securities issued using the shelf registration statement may be used for research and development programs, future acquisitions, general corporate purposes and to fund the Company's working capital requirements.

The new shelf registration statement has not yet become effective. The securities offered by Cytokinetics under this shelf registration statement may not be sold, nor may offers to buy the securities be accepted prior to the time the shelf registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offering will be made only by means of prospectus and a related prospectus supplement.

### **About Cytokinetics**

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs for the potential treatment of cardiovascular disease, cancer and other diseases. All of Cytokinetics' drug candidates and potential drug candidates have arisen from its research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at [www.cytokinetics.com](http://www.cytokinetics.com).

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the effectiveness of the shelf registration statement filed by Cytokinetics with the SEC and Cytokinetics' plans with respect to the issuance of securities under the shelf registration statement and its use of any resulting proceeds. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, risks and uncertainties relating to actions by the SEC regarding the shelf registration statement and the market for Cytokinetics' securities. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:  
Christopher S. Keenan  
Director, Investor Relations and Media  
(650) 624-3000

SOURCE: Cytokinetics, Inc.